AMBISOME COMPARED WITH AMPHOTERICIN B FOR HISTOPLASMOSIS IN AIDS PTS

Ambisome 与两性霉素 B 治疗艾滋病患者组织胞浆菌病的比较

• 批准号: 6121106
• 负责人: PHILIP C JOHNSON
• 金额: $ 1.51万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6121106
• 关键词: AIDS; AIDS therapy; amphotericin B; clinical research; combination chemotherapy; drug screening /evaluation; histoplasmosis; human subject; human therapy evaluation; microorganism disease chemotherapy; opportunistic infections

The aim of this studyis to compare AmBisome as induction therapy for the treatment of moderate to severe disseminated histoplasmosis in patients with AIDS. Patients will be randomized between treatment with IV AmBisome or amphotericin B for two weeks of induction therapy. Patients will then be treated with itraconazole for 10 additional weeks of consolidation therapy to complete a 12 week treatment course. This is a multicenter study of the Mycoses Study Group. Dr. Johnson is the PI for this nationwide study. The study has reached its total enrollment of 75 and will be analyzed soon.

本研究的目的是比较AmBisome作为诱导治疗中重度播散性组织胞浆菌病的艾滋病患者。 患者将在用IV AmBisome或阿替霉素B治疗之间随机分配两周的诱导治疗。 然后，患者将接受伊曲康唑额外10周的巩固治疗，以完成12周的疗程。 这是真菌病研究组的一项多中心研究。 约翰逊博士是这项全国性研究的PI。 该研究的总入组人数已达到75人，并将很快进行分析。